The pathologic role of mast cell was classically studied in allergic diseases such as asthma and anaphylaxis. 1 However, recently, the role of this multifunctional master cell has been actively investigated in the field of functional gastrointestinal disorder. Activation of mast cell has been suggested to increase intestinal permeability and promote visceral hypersensitivity in irritable bowel syndrome (IBS). 2 As one of the possible mechanisms, release of tryptase from mast cell, activation of protease-activated receptor 2 (PAR-2), and subsequent release of neuropeptides from afferent neurons in the intestine have been proposed through several studies. [3] [4] [5] In this issue of Gut and Liver, Liang et al. 6 investigated the expression of tryptase, PAR-2 and several neuropeptides in the colonic mucosal of healthy control and patients with IBS. The authors found that mRNA expression of tryptase and PAR-2 was significantly elevated in the patients with IBS compared to the control. Tryptase protein expression was also elevated in the patients with IBS. However, PAR-2 protein expression did not differ between the IBS patients and the control. The protein level of calcitonin gene-related peptide, vasoactive intestinal peptide, and substance P was significantly higher in the patients with diarrhea-type IBS (IBS-D) than in the control.
This study added precious evidence which supports the role of mast cell in the pathogenesis of IBS. In addition, the elevation of all neuropeptides in IBS-D only well corresponds with the results of some studies which showed mast cell hyperplasia is more common in IBS-D. 7, 8 However, this study has some limitations. The interaction between mast cell and intestinal never is bidirectional. 2 Neuropeptides can trigger activation of mast cell and conversely, activated mast cell can stimulate release of neuropeptides from nerve terminal. Therefore, elevation of both tryptase and neuropeptides in this study does not tell us which one is first. In addition, elevation of PAR-2 mRNA in the IBS patients did not led to the elevation of PAR-protein in this study. Another pathway which connects tryptase and the pathologic effects in IBS might be possible.
Recently, the role of gut microbiota has been highlighted in the pathogenesis of IBS. 9 Although there is still no convincing evidence, I think the change of gut microbiota might trigger activation of mast cell and subsequent visceral hypersensitivity. In-depth studies are required regarding the relationship between mast cell and the pathogenesis of IBS, considering the role of this tiny hero.
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